LACTOLOGY FOUNDATION

Fenpiverinium (ATC A03AB21) is a synthetic quaternary antimuscarinic used mainly as an antispasmodic in combination products for gastrointestinal, biliary, urinary and gynecological smooth‑muscle pain, but it is poorly studied in lactation and should generally be avoided or used with great caution in breastfeeding women.medpedia.framar+3

Below is an English, web‑page style toxico‑lactological monograph focused on class A03AB21.

Identity and ATC classification

Fenpiverinium is a synthetic quaternary ammonium antimuscarinic/anticholinergic agent classified in ATC group A03AB21 (synthetic anticholinergics, quaternary ammonium compounds) within drugs for functional gastrointestinal disorders.drugbank+3
It is often formulated as fenpiverinium bromide and appears predominantly in fixed‑dose combinations with an analgesic (e.g. metamizole) and a direct smooth‑muscle relaxant (e.g. pitofenone) for treatment of visceral spasmodic pain.wikidoc+1

Pharmacodynamics

Fenpiverinium acts as an antimuscarinic (anticholinergic) agent, competitively blocking acetylcholine at muscarinic receptors on smooth muscle cells in the gastrointestinal, biliary, urinary and uterine tracts.rxhive.zynapte+3
This leads to inhibition of parasympathetic tone, reduction of smooth muscle spasms and associated pain, and typical peripheral anticholinergic effects such as decreased glandular secretions and reduced gastrointestinal motility.drugs.ncats+2

Pharmacokinetics and special features

As a quaternary ammonium compound, fenpiverinium is expected to have poor lipid solubility and limited penetration across biological membranes, including the blood–brain barrier, which tends to limit central nervous system effects compared with tertiary anticholinergics.precision.fda+1
Data on its absorption, distribution, metabolism and excretion in humans are sparse; in clinical practice it is usually administered orally in low microgram doses within fixed combinations, and systemic exposure is presumed to be modest but not negligible.1mg+3

Therapeutic indications

Fenpiverinium‑containing combinations are indicated for symptomatic treatment of pain and discomfort due to smooth muscle spasm in the gastrointestinal tract (intestinal colic, spastic conditions), biliary tract (biliary colic), urinary tract (renal colic) and gynecological conditions such as dysmenorrhea.adipharm+3
Some national sources also list antimuscarinics such as fenpiverinium in the broader context of agents for functional gastrointestinal disorders and, historically, as antimuscarinic agents in other indications, but current use is almost exclusively as a component of antispasmodic–analgesic combinations.wikipedia+2

Posology and administration (general)

Adult oral dosing is product‑specific; in a representative fixed‑dose tablet containing metamizole 500 mg, pitofenone 5 mg and fenpiverinium bromide 0.1 mg, adults and adolescents ≥15 years typically receive 1–2 tablets two to three times daily, with a maximum of 6 tablets per day and treatment duration not exceeding 3 days without medical supervision.adipharm
Lower doses are recommended for children and adolescents (for example, 1 tablet two to three times daily for 12–15 years, ½ tablet two to three times daily for 9–12 years), and dosing must always follow the specific summary of product characteristics for the marketed product.medpedia.framar+1

Contraindications

Fenpiverinium must not be used in patients with hypersensitivity to the active substance or any component of the combination product.medpedia.framar+1
Typical anticholinergic contraindications apply, including untreated narrow‑angle glaucoma, prostatic hypertrophy with urinary retention, mechanical obstructive conditions of the gastrointestinal or urinary tract, tachyarrhythmias, severe heart failure, and myasthenia gravis; such conditions are listed or implied in product information for similar anticholinergic combinations.rxhive.zynapte+2

Warnings and precautions

Elderly patients and those with cardiovascular disease, autonomic neuropathy, chronic constipation, or urinary retention are at increased risk of anticholinergic adverse effects (e.g. confusion, constipation, urinary retention) and should receive fenpiverinium with particular caution.1mg+1
Combination products containing metamizole add further specific risks, notably rare but serious agranulocytosis and other blood dyscrasias, hypotension and anaphylactic reactions, which necessitate short‑term use, monitoring for signs of infection or shock, and avoidance in patients with known metamizole intolerance.1mg+1

Adverse effects and toxicity profile

Common adverse effects reflect peripheral anticholinergic activity and include dry mouth, decreased sweating, constipation, nausea, dizziness, flushing and possible tachycardia or palpitations.rxhive.zynapte+1
Less common but clinically significant reactions include urinary retention, blurred vision, intraocular pressure increase, confusion (especially in older adults), and, via the metamizole component, serious hematologic effects such as agranulocytosis, leukopenia and thrombocytopenia, sometimes accompanied by fever, sore throat and mucosal ulcerations.adipharm+2

Acute overdose

Overdose of fenpiverinium leads to a pattern of severe anticholinergic (antimuscarinic) toxicity, characterized by marked dry mucous membranes, mydriasis, tachycardia, hyperthermia, agitation, confusion, hallucinations, urinary retention, decreased bowel sounds and, in severe cases, seizures or cardiorespiratory compromise.rxhive.zynapte
Management is supportive and symptomatic, with early gastric decontamination when appropriate and intensive monitoring; product information notes the absence of a specific antidote for the fixed combination, while in principle physostigmine may be considered in life‑threatening anticholinergic syndrome by experienced clinicians.adipharm+1

Chronic toxicity and special organ risks

Long‑term safety data specific to fenpiverinium are limited; by analogy with other antimuscarinics, chronic use may exacerbate constipation, promote urinary retention and contribute to dental caries or oral candidiasis due to persistent xerostomia.1mg+1
Given the metamizole component in common combinations, repeated or prolonged use raises concern about cumulative risk of agranulocytosis and other serious hematologic toxicity, hence recommendations restrict duration and stress that prolonged therapy requires close medical supervision and periodic blood counts.1mg+1

Use in pregnancy

The safety of fenpiverinium in pregnancy has not been well established, and available product information generally advises that the drug or its combinations be avoided in pregnancy unless the potential benefit clearly outweighs possible risks.rxhive.zynapte+1
Metamizole‑containing products are often specifically contraindicated in the third trimester due to the risk of fetal and neonatal complications (e.g. premature closure of the ductus arteriosus, renal toxicity and bleeding), so any use of fenpiverinium combinations in pregnancy should be considered exceptional and short‑term.adipharm+1

General principles for use in lactation

Most medicines appear in breast milk in small amounts, and general lactation guidance considers many drugs compatible with breastfeeding when relative infant dose is below about 10% and when the drug lacks serious toxicity for the infant.medsafe+2
However, when a medicine is poorly studied in lactation and belongs to a class with potential for significant adverse effects in infants (e.g. anticholinergics, metamizole), authoritative sources recommend either choosing better‑studied alternatives or using the drug at the lowest effective dose for the shortest possible duration with careful infant monitoring.healthdirect+2

Fenpiverinium: expected transfer into breast milk

Fenpiverinium is a quaternary ammonium antimuscarinic with limited lipid solubility, which theoretically reduces its passage into breast milk compared with more lipophilic tertiary anticholinergics.drugs.ncats+1
Nonetheless, robust pharmacokinetic data in lactating women, including milk concentration and relative infant dose, are lacking, so any estimation of exposure remains theoretical and cannot substitute for direct studies or authoritative databases (e.g. LactMed) that clinicians should consult for case‑specific decisions.drugbank+2

Potential effects in breastfed infants

Anticholinergic exposure in infants can cause dryness of mucous membranes, reduced gastrointestinal motility with risk of constipation or ileus, urinary retention, hyperthermia due to decreased sweating, and, at higher exposures, tachycardia and central nervous system effects such as irritability or drowsiness.rxhive.zynapte+1
Because neonates and young infants have immature clearance mechanisms and are more sensitive to anticholinergic and hematologic toxicity, any fenpiverinium‑containing product used by the mother—particularly those also containing metamizole—raises concern for infant adverse effects and should prompt close observation for poor feeding, decreased urine output, constipation, unexplained fever or lethargy.mayoclinic+3

Maternal safety considerations during lactation

Breastfeeding women are themselves at increased risk from maternal adverse effects, such as dehydration and lactation difficulties from pronounced xerostomia, constipation, and urinary retention, especially in the early postpartum period when fluid balance and pelvic floor function may already be vulnerable.1mg+1
In addition, metamizole‑associated agranulocytosis presents a significant maternal risk during lactation, because infection and sepsis can rapidly compromise both maternal health and breastfeeding, underscoring the need to restrict duration of use and to avoid self‑medication without medical evaluation.adipharm+1

Lactation risk assessment for A03AB21 medicines

Given the absence of high‑quality studies of fenpiverinium in lactating women, its classification in a potentially problematic pharmacological class (anticholinergics) and frequent co‑formulation with metamizole, available information supports a cautious stance: fenpiverinium‑containing products should generally be avoided during breastfeeding when safer alternatives exist.drugbank+3
If a short course is considered indispensable for severe spasmodic pain unresponsive to better‑studied options, it should be prescribed at the lowest effective dose, for the shortest possible duration, with individualized assessment of infant age and comorbidities, and with explicit counselling about infant monitoring and the option of temporary breastfeeding interruption in high‑risk situations.medsafe+2

Safer alternatives for breastfeeding women

For many indications treated with fenpiverinium combinations (e.g. mild to moderate visceral colic, dysmenorrhea), non‑opioid analgesics such as ibuprofen and paracetamol/acetaminophen are generally considered compatible with breastfeeding and are well studied in this population.healthdirect+1
For antispasmodic needs, clinicians may consider agents with more established lactation data (depending on national availability) and non‑pharmacological measures (local heat, positional maneuvers, dietary modifications) before resorting to fenpiverinium products, especially in mothers of newborn or premature infants.mayoclinic+2

Practical recommendations for clinical practice

When encountering a lactating patient who is already taking a fenpiverinium‑containing combination, healthcare professionals should verify indication, dose and duration, check for maternal contraindications, and assess the breastfed infant for possible anticholinergic or hematologic adverse effects.medsafe+3
If continuation is deemed necessary, documentation of the risk–benefit discussion, provision of written advice on warning signs in the infant, and arrangement of follow‑up are essential; otherwise, a planned switch to a better‑studied analgesic or antispasmodic regimen is preferred.healthdirect+2

Patient counselling points for breastfeeding mothers

Mothers should be informed that fenpiverinium is an anticholinergic antispasmodic with limited but non‑negligible data in breastfeeding and that combination products often contain metamizole, which carries rare but serious blood toxicity.rxhive.zynapte+2
They should be instructed not to exceed prescribed doses or duration, to seek medical advice before repeating courses, and to contact a healthcare professional promptly if the infant develops poor feeding, constipation, reduced urine output, fever, unusual sleepiness or irritability while the mother is using the medicine.mayoclinic+2